ASX / MEDIA RELEASE
ResApp Initiates SMARTCOUGH-C Study Evaluating Efficacy
of ResAppDx for Diagnosing Childhood Respiratory Disease
SMARTCOUGH-C builds on ResApp’s highly successful Australian paediatric clinical
study which demonstrated accurate diagnosis of pneumonia, asthma/viral wheeze,
bronchiolitis, croup and upper respiratory tract infections. Analysis of the Australian
study data is progressing well and ResApp will release enhanced results early in the
new year.
ASX / MEDIA RELEASE ResApp Initiates SMARTCOUGH-C Study...
-
- There are more pages in this discussion • 60 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $176.2M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| RAP (ASX) Chart |
Day chart unavailable